Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

Second and third-generation ALK-TKI inhibitors have showed better activity and have replaced crizotinib in most of cases of advanced ALK-rearranged lung adenocarcinoma. The emergence of resistance adversely affects also the activity of these newer drugs; in particular, lorlatinib often shows multipl...

Full description

Bibliographic Details
Main Authors: Annamaria Catino, Rosanna Lacalamita, Simona De Summa, Francesco Pesola, Stefania Tommasi, Domenico Galetta
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Diagnostics
Subjects:
ALK-rearranged lung cancer
resistance mechanisms
lorlatinib
case report
Online Access:https://www.mdpi.com/2075-4418/12/3/682

Similar Items

Similar Items